Welcome to our dedicated page for Vext Science news (Ticker: VEXTF), a resource for investors and traders seeking the latest updates and insights on Vext Science stock.
Vext Science Inc. reports developments for a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. The company owns and operates cultivation facilities, manufacturing assets and dispensaries, and manufactures the Vapen brand of THC concentrates, edibles and distillate cartridges in Arizona.
Recurring news includes quarterly and annual financial results, operating cash flow and EBITDA updates, Ohio retail scaling, Arizona cultivation and manufacturing footprint decisions, and cannabis market activity across its core states. Company updates also cover shareholder meeting results, ownership disclosures, capital-structure matters involving multiple voting and subordinate voting shares, and trading references for its CSE-listed shares and OTCQX symbol VEXTF.
Vext Science (OTCQX: VEXTF) issued a corrected Q3 2025 results on November 20, 2025, revising EBITDA to $1.828M, Adjusted EBITDA to $1.625M and Adjusted EBITDA margin to 12.8% from previously disclosed higher amounts. Revenue for Q3 2025 was $12.7M, up 41% YoY, driven by expanded Ohio retail and steady Arizona performance. Year-to-date operating cash flow improved to $8.5M versus $(0.7)M a year earlier. The company expanded to five consolidated Ohio dispensaries and expects to reach an eight-dispensary cap in 2026. Vext refilled its MD&A to reflect the corrected metrics and scheduled a Q3 2025 earnings call on November 20, 2025.
Vext (OTCQX: VEXTF) reported Q3 2025 revenue of $12.7M, up 41% YoY, driven by expanded Ohio retail operations and steady Arizona store performance. Year-to-date operating cash flow reached $8.5M versus $(0.7)M in the prior-year period. Adjusted EBITDA for Q3 was $2.112M (16.7% margin), down from 32% a year earlier. The company reported a Q3 net loss of $2.628M and positive net cash from operations of $1.259M in the quarter. Vext now operates five consolidated Ohio dispensaries and says it is on track to reach the eight-license cap in 2026.
Management expects continued operational momentum, improved Q4 cash flow as Q3 inventory is worked through, and ongoing construction/licensing of three Ohio locations for 2026.
Vext Science (OTCQX: VEXTF) will release its financial results for the third quarter ended September 30, 2025 before market open on November 20, 2025. The company will host a conference call and webcast the same day at 8:00 AM ET to discuss the results.
Access details: participant dial-in +1-647-849-3159 or 1-833-752-3966; replay dial-in +1-412-317-0088 or 1-855-669-9658; conference ID 10204616; playback # 4318941 (expires December 4, 2025). A webcast will be available at https://www.gowebcasting.com/14537 and a replay will be posted on Vext's investor website.
Vext Science (OTCQX:VEXTF) has secured regulatory approval from the Ohio Department of Commerce to transfer ownership of the Herbal Wellness Center dispensary in Portsmouth, Ohio. The transfer is expected to complete by October 1, 2025, making Portsmouth Vext's fifth fully consolidated dispensary in Ohio.
The Portsmouth facility features a drive-thru and operates as both a medical and adult-use dispensary. Vext is actively working on three additional locations, progressing toward Ohio's eight-store maximum cap. The company maintains a strong presence in Ohio with a Tier 1 cultivation facility spanning 25,000 square feet (expandable to 50,000), a manufacturing facility, and multiple operational dispensaries across key locations.
Vext Science (OTCQX:VEXTF) reported exceptional Q2 2025 financial results, with revenue reaching $13.4 million, up 59% year-over-year and a sequential increase of $1.8 million. The company achieved record Adjusted EBITDA of $4.1 million, a significant increase from Q2 2024, and operating cash flow of $4.2 million with a 31% Cash Flow Margin.
The strong performance was driven by Ohio momentum, where Vext strengthened its retail footprint to four consolidated locations, and disciplined operations in Arizona. The company is on track to reach Ohio's state dispensary license cap of eight by early 2026. Notable Q2 developments include completing the Big Perm dispensaries acquisition, selling a Kentucky processing license for $0.9 million, and opening a new dispensary in Portsmouth, Ohio.
Vext Science (OTCQX: VEXTF), a cannabis operator with operations in Arizona and Ohio, has scheduled its Q2 2025 financial results announcement for August 20, 2025, before market open.
The company will host a conference call and webcast on the same day at 8:00 AM ET. Investors can access the call via dial-in numbers or webcast, with a replay available until September 3, 2025.
Vext Science (OTCQX:VEXTF) has secured a provisional license for its sixth Ohio dispensary in Fairfield, marking continued expansion in the state. The 3,825 square foot facility, expected to be operational in Q4 2025, will be strategically located next to Jungle Jim's International Market, benefiting from high consumer traffic.
The company will invest approximately $1 million in the build-out, funded through operating cash flow. The location features a drive-thru format and holds exclusive rights as the only permitted dispensary in Fairfield. This expansion advances Vext's progress toward Ohio's dispensary license cap of eight locations, complementing its existing vertically integrated operations including a Tier 1 cultivation facility and manufacturing operations.